Savant HWP Announces NIDA Funding for Pre-clinical Development of 18-MC as Potential Treatment for Addiction, Obesity
– Targeting the Brain’s Central Reward Pathway Offers Therapeutic Approach to Many Forms of Addiction, Overeating and Other Compulsive Behavior
– Human Clinical Trials to Begin in Early 2013
SAN CARLOS, Calif., Jan. 3, 2013 /PRNewswire/ — Savant HWP, Inc. today announced the receipt of a three-year grant to support the development of 18-MC (18-methoxycoronaridine) as a potential orally active ...
Continue Reading →